Trevi Therapeutics

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Trevi Therapeutics sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).

9 total trials 3 currently recruiting 6 completed early-phase tilt top decile by trial count

Trevi Therapeutics: 9 sponsored US clinical trials, 3 recruiting.

Trevi Therapeutics sponsors 9 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 6 completed. 1 of these trials are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prurigo, with 1 trials.

Top-decile sponsor footprint

Trevi Therapeutics ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

9 total, page 1 of 1

RECRUITING Phase 3

Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets

NCT07671911
RECRUITING Phase 1

A Food Effect Study to Evaluate the Relative Bioavailability of Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants

NCT07487740
RECRUITING Phase 1

NAL ER IPF Respiratory Function and Safety Study

NCT07036029
COMPLETED Phase 1

A Study of the Pharmacokinetic Interaction Between Pirfenidone, Nintedanib, and Nalbuphine Extended Release (NAL ER) in Healthy Participants

NCT07015398
COMPLETED Phase 1

Study of Nalbuphine ER in Participants With Hepatic Impairment

NCT04020016
COMPLETED Phase 2

PRISM Study-Pruritus Relief Through Itch Scratch Modulation

NCT03497975
COMPLETED Phase 2

Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis

NCT02174419
COMPLETED Phase 2

Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic Pruritus

NCT02143973
COMPLETED Phase 2

Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus

NCT02143648

Phase Distribution

PhaseTrial count
Phase 1 4
Phase 2 4
Phase 3 1

Therapeutic Areas

Prurigo 1
Nodularis Prurigo 1
Pruritus 1
Prurigo Nodularis 1
Idiopathic Pulmonary Fibrosis 1
Healthy Participants 1

What is open in the Trevi Therapeutics pipeline

3 recruiting of 9 indexed (33% open); 6 completed (67%).

Phase mix: 1 late (III/IV) vs 8 early (I/II) (early-phase heavy).

Top condition: Prurigo (1 trial), 5 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Trevi Therapeutics: open-pipeline peers nationwide

Peers matched on 9 registered trials and 33% open enrollment, not the therapeutic-area sidebar.

Trevi Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 246810 0%10%20%30%40%50% Total trials Recruiting share Trevi Therapeutics4D Molecular Therapeutics9 Meters BiopharmaAadi BioscienceAblynx, a Sanofi companyAaron CookAbivax S.A.Actuated MedicalAdagio Medical
Trevi Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Trevi Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 9 trials (± recruiting share)

Sponsors near 33% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Trevi Therapeutics page

9 registered trials is a research-attention snapshot, not an endorsement of Trevi Therapeutics or any single study.

  • 3 of Trevi Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Prurigo is the condition Trevi Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prurigo trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Trevi Therapeutics pipeline card: 9 registered trials from official public datasets.Report a data error.